The Roche and GSK-backed autoimmune disease drug developer has gone public in an upsized initial public offering after at least $138m in earlier funding.
Pandion Therapeutics, a US-based developer of autoimmune disease treatments, floated on Friday in a $135m initial public offering that represented an exit for pharmaceutical firms Roche and GlaxoSmithKline (GSK).
The company priced 7.5 million shares at $18.00 each, increasing the number of shares from 5.5 million and pricing them at the top of a $16 to $18 range. Its shares opened at $27.00 on the Nasdaq Global Market and closed at $18.10 on their first day.
Founded in 2016, Pandion…
